Merck's relebactam dubbed qualified infectious disease product
This article was originally published in Scrip
Executive Summary
Merck revealed on 4 September its investigational beta-lactamase inhibitor relebactam (MK-7655) was dubbed a qualified infectious disease product (QIDP) by the FDA.